1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Pink Sheet Podcast: CDER Director Retires, US FDA Guidance ‘Blizzard,’ Rare Pediatric Disease Program Hangs On

Pink Sheet editors discuss Center for Drug Evaluation and Research Director Patrizia Cavazzoni’s surprising retirement announcement, the importance of the large bolus of guidance documents that the FDA released 6 January, and the FDA’s decision to continue reviewing and granting rare pediatric disease designations even though the program lapsed.

Pink Sheet podcast
The bolus of guidances released 6 January cement FDA thinking on many subjects. • Source: Citeline/Shutterstock

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss Patrizia Cavazzoni’s legacy as Center for Drug Evaluation and Research Director in light for upcoming retirement (:32), the more than two dozen guidances that the US Food and Drug Administration issued in one day and why the move was unusual (12:42), as well as the reasons for the agency continuing to review and grant rare pediatric disease designation requests even though the program expired in December 2024 (18:48).

More On These Topics From The Pink Sheet

This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

More from US FDA

Peter Marks Resigns From US FDA, Warns Kennedy Does Not Want Truth On Vaccines

 
• By Sarah Karlin-Smith

In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."

Oncology Center Of Excellence Deputy Directors Kluetz, Theoret Join US FDA Exodus

 
• By Sue Sutter and Sarah Karlin-Smith

The April departures of Paul Kluetz and Marc Theoret follow resignations by other senior agency scientific staff and come on top of HHS’ plans to lay off 3,500 FDA employees.

Power Play: US FDA Likely Losing More Than Just Staff With Restructured Health Department

 
• By Sarah Karlin-Smith

About 3,500 full-time FDA employees are expected to be laid off as part of a restructuring of the Health and Human Services Department and experts questioned whether the cuts could be implemented without harming FDA’s core mission.

Government Pulls ‘For Sale’ Signs From US FDA’s White Oak Campus

 
• By Sue Sutter

The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.

More from Rare Diseases

England Reimburses Ultra-Rare Disease Drug Joenja, While EU Regulatory Review Drags On

 
• By Neena Brizmohun

Pharming has convinced NICE to reverse its rejection of its treatment for APDS by providing the health technology assessment institute with more data. It has also dropped the price it was asking for the drug, which has a list price of £352,000 per year per patient.

New EU Project Could Make Comparative Rare Diseases Trials More Feasible For Companies

 
• By Francesca Bruce

A new Innovative Health Initiative project will see the German health technology appraisal (HTA) body, IQWiG, work towards ensuring evidence generated in clinical studies meets the needs of HTA bodies and regulators.

US FDA Would See Another Austere Year With GOP Funding Bill, No PRV Reauthorization

 
• By Sarah Karlin-Smith

Democrats are raising concerns that the continuing resolution intended to fund the government for the remainder of fiscal year 2025 gives Trump too much power, though it is unclear whether the FDA would be as impacted as other agencies.